Price movement over the last 24 hours
American Superconductor Corporation vs Axogen Inc — how do they compare? American Superconductor Corporation trades at $35.49 (market cap $1.74B), while Axogen Inc trades at $40.21 (market cap $2.16B). The key difference: Axogen Inc is the larger of the two by market cap, and Axogen Inc is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | AXGN | |
|---|---|---|
Market Cap | $1.74B | $2.16B |
Sector | Technology | Technology |
52-Week High | $66.68 | $46.19 |
52-Week Low | $25.95 | $11.28 |
Enterprise Value | $1.61B | $2.08B |
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $35.96, down 3.26% today amid bearish technical signals. The stock shows strong fundamentals with recent earnings beats and robust profitability metrics including 44.73% net margin and 35.56% ROE. Revenue grew 34% year-over-year to $299.2 million in 2025, though cash flow trends show negative net cash flow of -$6.9M. Analyst sentiment remains positive with 53% buy ratings despite recent insider selling activity.
The outlook remains cautiously optimistic given strong order backlog growth of 40% and expanding role in AI energy infrastructure. Key risks include valuation concerns at 66.72x EV/EBITDA and acquisition-driven growth versus organic expansion. Earnings momentum and grid technology positioning provide upside potential if execution continues.
AXGN trades at $40.58, down 6.97% today, with neutral technical signals and mixed earnings performance. The company maintains strong gross margins of 75.01% but reported a net loss of $15.70 million in 2025. Analyst sentiment remains overwhelmingly positive with 16 buy ratings and a $47.60 consensus price target, representing 17% upside potential from current levels.
While AXGN shows promising revenue growth and institutional support, persistent net losses and recent earnings misses create execution risk. The stock's valuation appears stretched with a P/S ratio of 8.12 despite negative profitability metrics. Positive reimbursement developments and nerve repair market expansion provide growth catalysts if the company can achieve sustained profitability.
Trailing returns across standard periods
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →